Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
291.2 INR | +3.94% | +9.13% | +16.80% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.80% | 4.02B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.14% | 22.19B | |
-16.16% | 21.33B | |
-7.29% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon : India's Biocon to Launch Generic Drugs in Brazil via Libbs Farmaceutica Partnership